In January 2026, researchers at Tsinghua University published DrugCLIP in Science—a system that screened 500 million drug compounds against 10,000 human proteins in under 24 hours using eight GPUs. That is 10 million times faster than conventional molecular docking. The results are publicly available in GenomeScreenDB, giving any lab access to screening data across roughly half the human genome.
Meanwhile, the broader pipeline produced its first clinical proof. In June 2025, Insilico Medicine published Phase IIa results for rentosertib in Nature Medicine: patients on the drug gained 98 mL of lung capacity on average, while those on placebo lost 20 mL. In May 2026, Isomorphic Labs raised $2.1 billion to accelerate its IsoDDE drug design engine and push its first AI-designed candidates toward human trials by year-end.
Why it matters
The first end-to-end AI-designed drug has proved it works in patients—and $2.1 billion in new investment is betting more will follow.
Rentosertib Inhalation Formulation Clears IND for Direct-to-Lung Trial
Regulatory
China's drug regulator cleared an inhalation solution of rentosertib for Phase 1 clinical testing, the first direct-to-lung trial for an AI-designed drug. Preclinical data showed the inhaled form achieves higher lung exposure with lower systemic absorption than the oral tablet.
DrugCLIP Published in Science
Publication
Researchers from Tsinghua University publish DrugCLIP, demonstrating genome-wide virtual screening 10 million times faster than traditional docking, with validated hits including compounds more potent than existing antidepressants.
Phase IIa Results for First AI-Designed Drug Published in Nature Medicine
Publication
Insilico Medicine published full Phase IIa trial results for rentosertib in Nature Medicine, the first peer-reviewed clinical evidence that a fully AI-designed drug works in patients. Patients on 60 mg daily gained a mean 98 mL in lung capacity over 12 weeks; those on placebo lost 20 mL.
China Grants Rentosertib Breakthrough Therapy Designation
Regulatory
China's Center for Drug Evaluation granted Breakthrough Therapy Designation to rentosertib for idiopathic pulmonary fibrosis, the second major regulatory milestone for the drug after its 2023 FDA Orphan Drug Designation.
Rentosertib Becomes First AI-Designed Drug Named by USAN
Regulatory
The United States Adopted Names Council granted the official generic name 'rentosertib' to ISM001-055, the first drug where both the disease target and the molecular compound were identified by AI to receive a formal international drug name.
Recursion and Exscientia Merge
Industry
Two leading AI drug discovery companies complete their merger, combining phenomic screening with automated precision chemistry into an end-to-end platform with over 10 clinical programs.
First AI Drug Shows Efficacy in Phase IIa Trial
Clinical Trial
Insilico Medicine announces positive Phase IIa results for ISM001-055 in idiopathic pulmonary fibrosis—the first time a generative AI-designed drug demonstrates efficacy in patients.
Nobel Prize Awarded for AlphaFold
Recognition
Demis Hassabis and John Jumper receive the Nobel Prize in Chemistry for developing AlphaFold, recognizing AI's transformative impact on structural biology.
AlphaFold3 Expands Beyond Proteins
Breakthrough
DeepMind releases AlphaFold3, which predicts structures and interactions of proteins, DNA, RNA, and small molecules, enabling more comprehensive drug-target modeling.
First Fully AI-Designed Drug Enters Phase II Trials
Clinical Trial
Insilico Medicine's INS018_055 becomes the first entirely AI-discovered and AI-designed drug to enter Phase II clinical trials, marking a milestone for generative AI in drug development.
FDA Grants First Orphan Drug Designation to AI-Designed Molecule
Regulatory
The United States Food and Drug Administration grants its first Orphan Drug Designation to a molecule conceived entirely by AI, confirming such drugs can meet rigorous regulatory standards.
AlphaFold Database Expands to 200 Million Proteins
Data Release
DeepMind releases predicted structures for over 200 million proteins, covering nearly all known proteins and making structural data freely available to researchers worldwide.
Insilico Medicine Achieves 18-Month Drug Discovery
Milestone
Insilico Medicine identifies a novel target for idiopathic pulmonary fibrosis and advances a drug candidate to preclinical trials in 18 months—a process that typically takes 4-6 years.
AlphaFold2 Solves Protein Structure Prediction
Breakthrough
DeepMind's AlphaFold2 achieves near-experimental accuracy at the CASP14 competition, solving a 50-year grand challenge in biology and enabling structure-based drug discovery at scale.
First AI-Designed Drug Enters Human Trials
Milestone
A drug molecule designed entirely by artificial intelligence enters Phase I clinical trials for the first time, proving algorithms can create therapeutics worth testing in humans.
Scenarios
Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.
Log in to predict. Track your picks, climb the leaderboard.Log inSign Up
1
AI-Discovered Drugs Reach Market by 2028
The first drugs designed entirely by AI complete Phase III trials and receive regulatory approval. ISM001-055's positive Phase IIa results suggest this pathway is viable. If approved, AI-discovered drugs would validate the entire paradigm shift, potentially accelerating investment and adoption across the pharmaceutical industry. The key trigger would be successful Phase III results for Insilico's lead candidate or similar programs.
Discussed by: Industry analysts at Pharmaceutical Technology, Labiotech, and investment reports tracking Insilico Medicine and Recursion pipelines
Consensus—
2
DrugCLIP Database Yields Novel Therapeutics for 'Undruggable' Targets
The GenomeScreenDB database, containing screening results for 10,000 proteins against 500 million compounds, enables researchers to find drug candidates for proteins previously considered undruggable. DrugCLIP already identified candidate binders for TRIP12, a cancer- and autism-linked protein with no known small-molecule inhibitors. Multiple research groups could use the freely available database to pursue therapeutic leads that were computationally infeasible before.
Discussed by: Researchers commenting in Science, Chemistry World, and Inside Precision Medicine on TRIP12 and other difficult targets
Consensus—
3
Clinical Failures Reveal AI Prediction Limits
AI drug candidates fail in later-stage trials at rates similar to traditionally discovered drugs, revealing that computational predictions do not fully capture the complexity of human biology. Recursion already discontinued three clinical programs in 2025 for commercial reasons. If multiple AI-designed drugs fail Phase II or III trials, it could dampen enthusiasm and slow investment, though it would also provide valuable data for improving future models.
Discussed by: Harvard Medical School's Nicholas Polizzi, pharmaceutical industry analysts noting Recursion's discontinued programs
Consensus—
4
China-US Competition Fragments AI Drug Discovery
Growing technology competition between China and the United States leads to restrictions on sharing AI tools, protein databases, or drug discovery platforms across borders. DrugCLIP's Chinese origins could become relevant if export controls expand to cover AI drug discovery. This would fragment the currently global research ecosystem, slowing progress and creating parallel development tracks.
Discussed by: Geopolitical analysts tracking technology competition and export controls
Consensus—
5
Rentosertib Becomes First Approved AI-Designed Drug
With Phase IIa results published in Nature Medicine and regulatory designations in both the US and China, rentosertib is in Phase III discussions. If a Phase III trial launches in 2026 and shows durable efficacy, approval in 2028-2029 is plausible. This would mark the first drug where AI replaced human scientific hypothesis at both target discovery and compound design.
Resolves by: 2030-12-31
Source: FDA, EMA, or NMPA drug approval database
Discussed by: Insilico Medicine pipeline reports and analysts at Chemistry World and AJMC tracking the Phase III pathway for the first fully AI-discovered and AI-designed drug
An international consortium announced the complete sequencing of the human genome after 13 years and $2.7 billion. The project identified approximately 20,500 protein-coding genes, providing the first comprehensive map of potential drug targets. Researchers predicted a flood of new therapeutics based on genomic insights.
Outcome
Short Term
The pharmaceutical industry invested heavily in genomics-based drug discovery, expecting rapid returns that largely failed to materialize in the first decade.
Long Term
The genome provided the target list, but understanding protein structure and function remained bottlenecks. Only now, with AlphaFold predicting structures for the entire proteome, can researchers systematically screen the genome for drug candidates.
Why It's Relevant Today
DrugCLIP represents the fulfillment of the Human Genome Project's therapeutic promise. The 10,000 proteins screened correspond to roughly half the protein-coding genes identified 23 years ago—now finally accessible to systematic drug discovery.
Lipitor Discovery via Rational Drug Design (1985)
1985
What Happened
Warner-Lambert scientists used early computational modeling to design atorvastatin (Lipitor), targeting the HMG-CoA reductase enzyme's active site. The process took over 12 years from target identification to FDA approval in 1996. Lipitor became the best-selling drug in pharmaceutical history, generating over $125 billion in sales.
Outcome
Short Term
Lipitor validated structure-based drug design as a viable approach, though computational limitations meant most work still required extensive laboratory screening.
Long Term
The success established the paradigm that understanding protein structure enables rational drug design—but computational power and structural data remained limiting factors for decades.
Why It's Relevant Today
Where Lipitor's discovery required years of computational work on a single target, DrugCLIP can now screen the entire human proteome in under a day. The fundamental approach—matching molecular shapes to protein binding sites—remains the same, but the scale has expanded by orders of magnitude.
High-Throughput Screening Revolution (1990s)
1990-1999
What Happened
Pharmaceutical companies invested billions in robotic systems capable of physically testing up to one million compounds per day against disease targets. The approach promised to accelerate drug discovery by brute-force screening of chemical libraries. Major hits included gefitinib and maraviroc, now standard treatments for cancer and HIV respectively.
Outcome
Short Term
High-throughput screening became industry standard, but hit rates remained low (typically 0.01-0.1%) and the approach required synthesizing or purchasing physical compounds.
Long Term
The method plateaued as companies exhausted their existing compound libraries. Virtual screening emerged as a faster, cheaper alternative, but remained computationally limited until recent AI advances.
Why It's Relevant Today
DrugCLIP represents virtual screening's maturation into a practical replacement for physical high-throughput screening. Where robots tested one million compounds daily, AI now evaluates 500 million computationally—against 10,000 targets simultaneously rather than one.
